Table 1.
Demographics, Comorbidities, and Clinical Characteristics
|
N=152
(distinct patients) |
||
|---|---|---|
| n or median | % or IQR | |
| Demographics | ||
| Age, years, median (IQR) | 62 | 52.5–72 |
| Sex | ||
| Female | 63 | 41% |
| Male | 89 | 59% |
| Race | ||
| Hispanic | 48 | 32% |
| Non-Hispanic black | 60 | 39% |
| Non-Hispanic white | 11 | 7% |
| Asian | 9 | 6% |
| Other | 12 | 8% |
| Unknown | 12 | 8% |
| Co-infection | ||
| Blood only | 61 | 40% |
| Respiratory only | 70 | 46% |
| Both blood and respiratory | 21 | 14% |
| Comorbidities | ||
| Charlson Comorbidity Score | 2 | 1–4 |
| Immunocompromised* | 84 | 55% |
| Medications Received for COVID-19 | ||
| Biologics** | 26 | 17% |
| Acute steroid use | 44 | 29% |
| Outcomes | ||
| Length of stay, days | 13 | 6–21 |
| Still admitted at time of analysis | 42 | 28% |
| Discharged alive | 24 | 16% |
| Deceased | 86 | 57% |
*Immunocompromised includes chronic diabetes, HIV, hepatitis C, active malignancy, organ transplant, rheumatologic disease, or chronic receipt of immunosuppressive medications. **Patients received anakinra, tocilizumab, sarilumab, or leronlimab either through randomized clinical trial or compassionate use; unknown if trial patients received placebo or study medication.